Developing new methods for creating important chemical structures using innovative chemistry.
Official title: Selective Chemical Synthesis and Catalysis Enabled by Single-Electron Oxidation of Aromatic N-oxides
Funded at Indiana University Indianapolis · NIH-11066533 · Data updated 2026-11-12
This study is looking at new ways to create and improve medicines using special chemistry techniques, which could help develop better treatments for various diseases that patients may face.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | July 15, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $391,837 |
| NIH project number | 5R35GM150542-03 |
| Project ID | NIH-11066533 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals with conditions that require innovative therapeutic agents or improved drug formulations.
✕Less likely to help
Patients with conditions that are not addressed by new chemical synthesis or those who do not require novel therapeutic agents may not receive benefits from this research.
What this research studies
This research focuses on creating new synthetic strategies and catalysts by utilizing single-electron transfer chemistry of aromatic N-oxides, which are versatile and readily available compounds. The goal is to enhance our understanding of this chemistry to enable the development of new therapeutic agents and improve the synthesis of existing ones. By exploring this unconventional approach, the research aims to facilitate the design and manufacture of medicines that can effectively manage and treat various diseases. Patients may benefit from advancements in drug development resulting from this innovative chemical synthesis.
Why it matters
Potential benefit: If successful, this research could lead to faster and more efficient development of new medications for various diseases.
How similar studies have gone: Other research has shown promise in utilizing unconventional chemistry for drug development, indicating potential success for this innovative approach.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Deng, Yongming — Indiana University Indianapolis
- Study coordinator: Deng, Yongming
Related research
Other NIH-funded projects on the same topics.
-
Adapting flow cytometry to detect childhood leukemias in Kenya using a single-test screen
A low-cost, blood-based flow cytometry screen in Kenya aims to detect and triage suspected leukemias in children and young adults.
-
Dementia care staff study: adapting a US survey for use in many countries
A study is adapting and testing a survey for dementia care workers in the US, Brazil, Switzerland, and Ghana to help understand why workers stay in their jobs and how to improve care.
-
Dementia care staff study: adapting a survey for use in many countries
A multinational study will adapt and test a U.S. dementia-care worker survey in Brazil, Switzerland, and Ghana to help understand why staff stay in or leave long-term care settings.
-
Study of Dementia Care Staff in 4 Countries: Adapting Caregiver Surveys Across Cultures
A multinational project will adapt and test a dementia care worker survey so researchers can compare care environments across the US, Brazil, Switzerland, and Ghana.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.